选择语言

FGL1蛋白-肿瘤免疫治疗新通路

FGL1是纤维蛋白原蛋白质家族的成员。正常情况下,FGL1在肝脏低水平表达,但在前列腺癌、黑素瘤等许多类型的癌症中均高表达。最新研究表明,FGL1是LAG-3的主要配体并具有高亲和力,表明FGL1的发现将开启肿瘤免疫治疗新时代,为肿瘤的免疫治疗提供新契机。
为满足市场需求,ACROBiosystems开发了由HEK293表达的多种属(Human, Mouse, Cyno)和多种标签(Fc, His)的FGL1重组蛋白,更有AviTag生物素标记的FGL1蛋白可以助力于您的药物开发。ACRO对FGL1蛋白的纯度、活性等性能进行了验证,并可免费提供相应的Protocol。

应用

产品列表

活性验证

FGL1的生物活性经ELISA验证
FGL1的生物活性经ELISA验证

Immobilized Human LAG-3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) at 10 μg/mL (100 μL/well) can bind Human FGL1, Fc Tag (Cat. No. FG1-H5258) with a linear range of 0.02-0.156 μg/mL.

Protocol

FGL1的生物活性经ELISA验证

Serial dilutions of Anti-LAG3, Neutralizing Antibody were added into Human FGL1, Fc Tag (Cat. No. FG1-H5258): Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) binding reactions. The half maximal inhibitory concentration (IC50) is 0.42303 μg/mL.

Protocol

FGL1的生物活性经BLI验证
FGL1的生物活性经BLI验证

Loaded Human LAG-3, Fc Tag (Cat. No. LA3-H5255) on Protein A Biosensor, can bind Human FGL1, His Tag (Cat. No. FG1-H52Hy) with an affinity constant of 7.09 nM as determined in BLI assay (ForteBio Octet Red96e).

Protocol

FGL1的生物活性经Cell-base assay验证
FGL1的生物活性经Cell-based assay验证

FACS assay shows that Human FGL1, Fc Tag (Cat. No. FG1-H5258) can bind to 293T cells overexpressing human LAG3. The concentration of Human FGL1 is 3 μg/mL (Routinely tested).

Protocol

  • 背景
  • 应用
  • 产品列表
  • 活性验证